• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

1.339 -0.751 (-35.93%)
Streaming Delayed Price Updated: 2:38 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,877,091
Open 2.230
Bid (Size) 1.310 (6,500)
Ask (Size) 1.340 (900)
Prev. Close 2.090
Today's Range 1.310 - 2.400
52wk Range 2.030 - 5.744
Shares Outstanding 11,184,423
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives FDA Clearance For STAR-001 Pediatric CNS Cancer Trial
Today 9:25 EDT
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
Today 7:29 EDT
From Lantern Pharma Inc.
Via Business Wire

Performance

YTD
-56.9%
-56.9%
1 Month
-47.9%
-47.9%
3 Month
-61.5%
-61.5%
6 Month
-69.1%
-69.1%
1 Year
-63.3%
-63.3%

More News

Read More
News headline image
RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem
Today 7:00 EDT
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Fourth Quarter And Fiscal Year 2025 Results Webcast
March 24, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
March 23, 2026
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST
March 21, 2026
Via ACCESS Newswire
News headline image
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19
March 16, 2026
Via ACCESS Newswire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Present AI-Driven Neuro-Oncology Strategy at Glioblastoma Summit
February 10, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
February 10, 2026
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Receives FDA Orphan Drug Designation For LP-284 In Soft Tissue Sarcomas
January 20, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
January 20, 2026
From Lantern Pharma Inc.
Via Business Wire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Establishes AI Center of Excellence and Advanced Agentic Labs in India
January 12, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies
January 12, 2026
From Lantern Pharma Inc.
Via Business Wire
News headline image
New to The Street Show #710 Airs Tonight at 6:30 PM EST on Bloomberg Television
December 27, 2025
Via ACCESS Newswire
BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
December 03, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
December 03, 2025
From Lantern Pharma Inc.
Via Business Wire
InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Q3 2025 Results and Highlights AI-Driven Clinical Progress
November 13, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 13, 2025
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
November 13, 2025
Via Benzinga
News headline image
Lantern Pharma Earnings Preview ↗
November 12, 2025
Via Benzinga
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) CEO Discusses AI-Driven Cancer Drug Development in FintechTV Interview at NYSE
November 10, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
New to The Street to Broadcast Show Number 698 on Bloomberg - Saturday, November 8, 2025, at 6:30 PM EST
November 08, 2025
Via ACCESS Newswire
News headline image
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows
November 07, 2025
Via ACCESS Newswire
AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Sets Nov. 13 Webcast to Review Q3 2025 Results and AI Platform Developments
November 06, 2025
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
November 06, 2025
From Lantern Pharma Inc.
Via Business Wire

Frequently Asked Questions

Is Lantern Pharma Inc. - Common Stock publicly traded?
Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
What exchange does Lantern Pharma Inc. - Common Stock trade on?
Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
What is the current price of Lantern Pharma Inc. - Common Stock?
The current price of Lantern Pharma Inc. - Common Stock is 1.339
When was Lantern Pharma Inc. - Common Stock last traded?
The last trade of Lantern Pharma Inc. - Common Stock was at 03/27/26 02:38 PM ET
What is the market capitalization of Lantern Pharma Inc. - Common Stock?
The market capitalization of Lantern Pharma Inc. - Common Stock is 14.98M
How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
Lantern Pharma Inc. - Common Stock has 15M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap